131 related articles for article (PubMed ID: 38469902)
1. A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.
Fettiplace A; Matis-Mitchell S; Molodetskyi O; Söderbergh M; Oscarsson J; Lin M; Ravikiran S; Billger M; Ambery P
Expert Opin Drug Saf; 2024 Apr; 23(4):477-486. PubMed ID: 38469902
[TBL] [Abstract][Full Text] [Related]
2. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
[TBL] [Abstract][Full Text] [Related]
3. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.
Lin X; Parks D; Painter J; Hunt CM; Stirnadel-Farrant HA; Cheng J; Menius A; Lee K
Drug Saf; 2012 Oct; 35(10):865-75. PubMed ID: 22928730
[TBL] [Abstract][Full Text] [Related]
4. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
Parks D; Lin X; Painter JL; Cheng J; Hunt CM; Spraggs CF; Nelson JJ; Curtis L; Menius JA; Lee KR
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):571-8. PubMed ID: 23300062
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
Heerspink HJL; Greasley PJ; Ahlström C; Althage M; Dwyer JP; Law G; Wijkmark E; Lin M; Mercier AK; Sunnåker M; Turton M; Wheeler DC; Ambery P
Nephrol Dial Transplant; 2024 Feb; 39(3):414-425. PubMed ID: 37632201
[TBL] [Abstract][Full Text] [Related]
6. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Heerspink HJL; Kiyosue A; Wheeler DC; Lin M; Wijkmark E; Carlson G; Mercier AK; Åstrand M; Ueckert S; Greasley PJ; Ambery P
Lancet; 2023 Nov; 402(10416):2004-2017. PubMed ID: 37931629
[TBL] [Abstract][Full Text] [Related]
7. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
[TBL] [Abstract][Full Text] [Related]
8. Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.
Stern EP; Host LV; Wanjiku I; Escott KJ; Gilmour PS; Ochiel R; Unwin R; Burns A; Ong VH; Cadiou H; O'Keeffe AG; Denton CP
Arthritis Res Ther; 2022 Jun; 24(1):130. PubMed ID: 35650639
[TBL] [Abstract][Full Text] [Related]
9. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Nelson JB; Fizazi K; Miller K; Higano C; Moul JW; Akaza H; Morris T; McIntosh S; Pemberton K; Gleave M
Cancer; 2012 Nov; 118(22):5709-18. PubMed ID: 22786751
[TBL] [Abstract][Full Text] [Related]
10. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
12. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.
Shantakumar S; Landis S; Lawton A; Hunt CM
Regul Toxicol Pharmacol; 2016 Jun; 77():257-62. PubMed ID: 27025923
[TBL] [Abstract][Full Text] [Related]
14. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
15. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
Watkins PB; Desai M; Berkowitz SD; Peters G; Horsmans Y; Larrey D; Maddrey W
Drug Saf; 2011 Mar; 34(3):243-52. PubMed ID: 21332248
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).
Dawson N; Payne H; Battersby C; Taboada M; James N
J Cancer Res Clin Oncol; 2011 Jan; 137(1):99-113. PubMed ID: 20390429
[TBL] [Abstract][Full Text] [Related]
18. Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.
Li J; Liu Y; Qian J; Wu L; Kemp J; Nii M; Tomkinson H; Zuo Y; Ranson M; Usami M
Cancer Chemother Pharmacol; 2012 Jul; 70(1):57-63. PubMed ID: 22618295
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Watkins PB; Lewis JH; Kaplowitz N; Alpers DH; Blais JD; Smotzer DM; Krasa H; Ouyang J; Torres VE; Czerwiec FS; Zimmer CA
Drug Saf; 2015 Nov; 38(11):1103-13. PubMed ID: 26188764
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
Schelman WR; Liu G; Wilding G; Morris T; Phung D; Dreicer R
Invest New Drugs; 2011 Feb; 29(1):118-25. PubMed ID: 19763400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]